If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

The drugmaker – which was known as Mallinckrodt beforemerging with Endo and rebranding as Keenova last year – said that ...

Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium ...

The Phase 4 retrospective study evaluates previously generated XIAFLEX® (collagenase clostridium histolyticum) data for recurrent Dupuytren contracture after surgery. Findings suggest XIAFLEX may ...

After thriving in the market for more than a decade as the only treatment for Dupuytren's contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could ...

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for ...

DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...

Shares of Auxilium Pharmaceuticals Inc. climbed 17.4 percent Wednesday on news that the FDA had approved Xiaflex (collagenase Clostridium histolyticum) as the first drug in the U.S. to treat Dupuytren ...

-- Endo presents encore data of research evaluating the impact of PD on erectile function and female partners, as well as the efficacy of XIAFLEX® treatment -- DUBLIN, May 19, 2015 /PRNewswire/ -- ...

Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic ...